The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.